US4585789A
Expired / Lapsed
US
⏱️ 0.0 years remaining
New furanone derivatives, process for preparation thereof and use thereof
Assignee: Astellas Pharma Inc
•
Filing: 1983-06-29
•
Granted: 1986-04-29
•
Expires: 2003-06-29
Abstract
Abstract Described are compounds of the formula: <IMAGE> Wherein A is a lower alkylene group; R1 is a carboxy, hydroxy, lower alkoxycarbonyl, lower alkoxycarbonylamino, phenyl(lower)alkyloxy, benzoyloxy or lower alkanoyloxy group; R2 is a hydrogen or halogen atom or a halo(lower)alkyl group; R3 is a hydrogen or halogen atom; R4 is hydroxy, lower alkoxy, lower alkanoyloxy or lower alkoxycarbonyloxy group; and R5 is a hydrogen or halogen atom; Q is the number of double bonds which is equal to 0 or 1; n is an integer of 0 or 1, provided that when Q is 0, n is 1 and when Q is 1, n is 0.
Inventors
- 👤 Masanori Okamoto
- 👤 Itsuo Uchida
- 👤 Kazuyoshi Umehara
- 👤 Masanobu Kohsaka
- 👤 Hiroshi Imanaka
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 17:34
CPC Classifications
C; C07; C07D; C07D303/00; C07D303/02; C07D303/12; C07D303/18; C07D303/20; C07D303/22; C07D307/00; C07D307/02; C07D307/04; A; A61; A61P; A61P27/00; A61P27/02; A61P27/12; C07C; C07C43/00; C07C43/02; C07C43/03; C07C43/14; C07C43/164; C07C43/166; C07D307/26; C07D307/30; C07D307/32; C07D307/33; C07D307/34; C07D307/56; C07D307/58; C07D307/60; C07D309/00; C07D309/02; C07D309/08; C07D309/10; C07D309/12; C12; C12N; C12N1/00; C12N1/14; C12N1/145; C12P; C12P17/00; C12P17/02; C12P17/04; C12R; C12R2001/00; C12R2001/645; Y; Y02; Y02P; Y02P20/00; Y02P20/50; Y02P20/55
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
116 words
A compound of the following formula or its pharmaceutically acceptable salt: ##STR6## wherein A is a lower alkylene group; R 1 is a carboxy, hydroxy, lower alkoxycarbonyl, lower alkoxycarbonylamino phenyl(lower)alkyloxy, benzoloxy, or lower alkanoyloxy group; R 2 is a hydrogen or halogen atom or a halo(lower)alkyl group; R 3 is a hydrogen or halogen atom; R 4 is a hydroxy, lower alkoxy, lower alkanoyloxy or lower alkoxycarbonyloxy group and R 5 is a hydrogen or halogen atom; Q is the number of double bonds which is equal to 0 or 1; n is an integer of 0 or 1, provided that when Q is 0, n is 1 and when Q is 1, n is 0.
Claim 2
Dependent Claim
116 words
A compound of the following formula or its pharmaceutically acceptable salt: ##STR6## wherein A is a lower alkylene group; R 1 is a carboxy, hydroxy, lower alkoxycarbonyl, lower alkoxycarbonylamino phenyl(lower)alkyloxy, benzoloxy, or lower alkanoyloxy group; R 2 is a hydrogen or halogen atom or a halo(lower)alkyl group; R 3 is a hydrogen or halogen atom; R 4 is a hydroxy, lower alkoxy, lower alkanoyloxy or lower alkoxycarbonyloxy group and R 5 is a hydrogen or halogen atom; Q is the number of double bonds which is equal to 0 or 1; n is an integer of 0 or 1, provided that when Q is 0, n is 1 and when Q is 1, n is 0.
Claim 3
Dependent Claim
34 words
A pharmaceutical composition of aldose reductase inhibitory activity comprising an effective amount of a compound as defined in claim 1 or its pharmaceutically acceptable salt in admixture with a substantially non-toxic carrier or excipient.
Claim 4
Independent Claim
137 words
A method comprising administering an effective amount of a compound or its pharmaceutically acceptable salt to a subject in need of treatment of diabetic cataract and/or neuropathy, said compound being of the formula: ##STR7## wherein A is a lower alkylene group; R 1 is a carboxy, hydroxy, lower alkoxycarbonyl, lower alkoxycarbonylamino, phenyl(lower)alkyloxy, benzoyloxy or lower alkanoyloxy group; R 2 is a hydrogen or halogen atom or a halo(lower)alkyl group; R 3 is a hydrogen or halogen atom; R 4 is hydroxy, lower alkoxy, lower alkanoyloxy or lower alkoxycarbonyloxy group; and R 5 is a hydrogen or halogen atom; Q is the number of double bonds which is equal to 0 or 1; n is an integer of 0 or 1, provided that when Q is 0, n is 1 and when Q is 1, n is 0.
Claim 5
Independent Claim
137 words
A method comprising administering an effective amount of a compound or its pharmaceutically acceptable salt to a subject in need of treatment of diabetic cataract and/or neuropathy, said compound being of the formula: ##STR7## wherein A is a lower alkylene group; R 1 is a carboxy, hydroxy, lower alkoxycarbonyl, lower alkoxycarbonylamino, phenyl(lower)alkyloxy, benzoyloxy or lower alkanoyloxy group; R 2 is a hydrogen or halogen atom or a halo(lower)alkyl group; R 3 is a hydrogen or halogen atom; R 4 is hydroxy, lower alkoxy, lower alkanoyloxy or lower alkoxycarbonyloxy group; and R 5 is a hydrogen or halogen atom; Q is the number of double bonds which is equal to 0 or 1; n is an integer of 0 or 1, provided that when Q is 0, n is 1 and when Q is 1, n is 0.
Claim 6
Dependent Claim
11 words
A compound according to claim 1, which is 3-(4-hydroxy-5-oxo-3-phenyl-2,5-dihydro-2-furyl) propionic acid.
References Cited (Backward Citations)
US2841594A
Cited
US3113939A
Cited
US3509209A
Cited
US3873575A
Cited
US3564020A
Cited
US3665014A
Cited
US3813416A
Cited
DE1920176A1
Cited
US3838168A
Cited
US3940424A
Cited
US4010170A
Cited
US4214092A
Cited
US4508914A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-04-28 | 1989-10-28 | 1990-04-29 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-04-28 | 1993-10-28 | 1994-04-29 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-04-28 | 1997-10-28 | 1998-04-29 | $7700.00 | Window Closed / Lapsed |